Oesophagogastric cancers are cancers of the oesophagus and stomach. Of the most common cancers, they have among the worst outcomes. The overall ten year survival rate is just twelve per cent for oesophageal cancer and sixteen per cent for stomach cancer. For all other cancers combined, it is fifty per cent. Around 12,500 people are diagnosed with oesophagogastric cancer in the UK every year, and around 11,400 people die from it.
Part of what makes oesophagogastric cancer so difficult to treat is that it is hard to detect early, and does not always respond well to treatment. Across the UK, an average of 38.7 per cent of all cancers are detected at stages one and two. For oesophageal cancer, fewer than fifteen per cent of cases are caught this early. Even when cases are caught early, outcomes remain much worse than for most other common cancers. Fewer than half of people survive beyond five years. For breast, prostate, colorectal and melanoma cancers detected at a similar stage, the figure is around eighty five per cent.
In 2017, researchers Xin Lu and Mark Middleton identified oesophageal cancer as a strategic priority for Oxford Cancer. This led to an Oesophageal Cancer Centre of Excellence and a dedicated community of Oxford-based clinicians working to advance the field. The centre brings together Oxford’s patient advocacy team and internationally respected clinical researchers. It aims to develop new treatments that could mean healthier, happier lives, and potentially new cures. It draws on Oxford’s scientific expertise and a global network of academic and commercial partners.
The centre’s flagship work spans several areas. Its work on new drugs and immunotherapies aims to bring the progress seen in other cancers to oesophagogastric cancer as quickly as possible. In melanoma, for example, combination immunotherapy has taken five year survival from almost zero to over fifty per cent in some patients. A separate programme focuses on better biomarkers. It is still hard to know which treatment will work best for each patient, and ongoing studies aim to tailor therapy more precisely to each person.
Another research programme aims to make advanced pathology assessments standard NHS practice. This would support more targeted therapies and help more patients join relevant clinical trials. Finally, work on surgery itself looks at the physical and digestive side effects of treatment, since removing these tumours means long, complex surgery. It also makes sure new surgical techniques are properly tested before wider use.
Together, these programmes aim to close the gap in outcomes between oesophagogastric cancer and more survivable cancers. They combine better early detection, smarter use of existing treatments and continued investment in research. This article is based on information from Oxford Cancer.

You might also find these useful: